Model identifies unusual strength in this stock at the moment. Its been a long-term underperformer.PSH has had dealings with RIC in the past and they have both been rather odd recently.
OAR Chris Judd's Talk Ya Book: Orthocell building on 'enormous potential' with steady growth - and US push to come
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025